NCT05442437 (CS-hUC-MSCs) is a EARLY_PHASE1 clinical trial of hUCMSCs in HBV, sponsored by Zhongnan Hospital.

Who is sponsoring NCT05442437?

NCT05442437 is sponsored by Zhongnan Hospital.

What drugs are being tested in NCT05442437?

Interventions in NCT05442437: hUCMSCs.

Is NCT05442437 still recruiting?

NCT05442437 is currently completed. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT05442437: CS-hUC-MSCs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV

Completed EARLY_PHASE1 Last updated 1 December 2023

What this trial tests

EARLY_PHASE1 trial testing hUCMSCs in HBV in 24 participants. Completed in 31 December 2022.

Timeline

8 September 2019

Primary endpoint
1 July 2022

31 December 2022

Quick facts

Lead sponsor	Zhongnan Hospital
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	8 September 2019
Primary completion	1 July 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

hUCMSCs — full drug profile →

Conditions studied

HBV — all drugs for HBV →

Sponsor

Zhongnan Hospital

Who can join

Adults 18 to 65, any sex, with HBV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to observe the safety ,tolerability ,Efficacy dose of human umbilical cord mesenchymal stem cells in patients of decompensated liver cirrhosis with HBV.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M, Bayati P, Mojtabavi N. · · 2024 · cited 18× · PMID 38886859 · DOI 10.1186/s13287-024-03782-5
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Huang WC, Li YC, Chen PX, Ma KS, et al · · 2025 · cited 14× · PMID 39762946 · DOI 10.1186/s13287-024-04127-y
Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284
From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy.
Bozorgi V, Babaahmadi M, Salehi M, Vafaeimanesh J, et al · · 2025 · cited 4× · PMID 40764597 · DOI 10.1186/s13287-025-04535-8
Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial.
Qin X, Chen J, Zhang HN, Du L, et al · · 2025 · cited 1× · PMID 41024792 · DOI 10.4240/wjgs.v17.i9.109980
Stem cell-based therapeutic strategies for liver aging.
Niu H, Wang YN, Ding Y, Lin YQ, et al · · 2025 · cited 1× · PMID 40620500 · DOI 10.1016/j.livres.2025.04.003
The research of human umbilical cord mesenchymal stem cells therapy in decompensated liver cirrhosis associated with hepatitis virus B: a long-term follow up analysis of a single-center, on-limits and stepped research.
Qin X, Chen J, Du L, Ma Y, et al · · 2024 · DOI 10.21203/rs.3.rs-3736389/v1

Verify or expand the search:

Other recruiting trials for HBV

Currently open trials in the same condition.

NCT07529171 — HBV Reactivation in Immunocompromised Patients (REANT STUDY) · recruiting
NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
NCT06372990 — Rapid T-cell Analysis Test in Patients With Chronic HBV and HBV/HDV Disease · recruiting
NCT06746701 — Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA. · recruiting
NCT05781568 — Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) · recruiting

Other Zhongnan Hospital trials

Trials by the same sponsor.

NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05442437 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05442437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing